[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605197":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":36,"locations":41,"responsibleParty":60,"collaborators":63,"id":69,"slug":31,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":31,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":31,"enrollmentInfo":77,"targetDuration":31,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":43,"whyStopped":31,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Month 6","EXPERIMENTAL","All clinics will begin the study in the control phase. The intervention will be introduced in 5 steps with 5-6 clinics per step at intervals of 6 months. The transition phase from the control period to the intervention period will last 1 month and provide time for rolling out educational content and access to the MASLD fibrosis risk assessment EHR alert. A computer-generated randomization program will assign clinics to one of the 5 pre-defined transition steps (months 6, 12, 18, 24, and 30).",[13],"Other: EHR alert",{"label":15,"type":10,"description":11,"interventionNames":16},"Month 12",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Month 18",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Month 24",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Month 30",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"EHR alert","Diagnoses of MASLD (based on ICD 9\u002F10 code) in a patient's EHR history, visit, or problem list, will cue a non-interruptive alert to appear and prompt clinicians to use the integrated EPIC© FIB-4 calculation SmartPhrase. The tool displays the FIB-4 risk score, the advanced fibrosis risk, and the clinical guidance. LSM by ultrasound with elastography will be recommended for patients with FIB-4 \\>1.3 (FIB-4 \\>2.0 if age \\>65) and the decision support will urge clinicians to order US with elastography through the SmartSet. LSM results will be documented in the EHR and categorized as low-risk MASLD (LSM \\\u003C8 kPa) or advanced fibrosis (LSM \\>8 kPa). Results will be disseminated to the ordering PCPs and the patients. PCPs will receive information on patient counseling for MASLD, and the expanding roles of weight loss, reduced alcohol use, and exercise on disease management. PCPs will be encouraged to refer patients with advanced fibrosis to a hepatology specialist, in accordance with guidelines.",[15,18,21,24,9],null,[33],{"name":34,"affiliation":5,"role":35},"Andrew Schreiner, MD, MSCR","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":31,"email":40},"CONTACT","(843) 876-0888","schrein@musc.edu",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Charleston","South Carolina","29425","United States",{"type":49,"coordinates":50},"Point",[51,52],-79.93275,32.77632,{"lat":52,"lon":51},[55,59],{"name":56,"role":38,"phone":57,"phoneExt":31,"email":58},"Chloe Bays, MPH","843-876-8688","coopechl@musc.edu",{"name":34,"role":38,"phone":57,"phoneExt":31,"email":40},{"type":35,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Andrew Schreiner","Associate Professor-Faculty",[64,67],{"name":65,"class":66},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"name":68,"class":66},"National Institutes of Health (NIH)","100605197",false,"NCT07159386","Advanced Fibrosis Detection for MASLD in Primary Care","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care","Patients\n\nInclusion Criteria:\n\n* Patients with a diagnosis code for MASLD\n* Type 2 diabetes mellitus will\n\nExclusion Criteria:\n\n* All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded.\n* pregnant women.\n\nClinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices.\n\nInclusion criteria:\n\n1\\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study.\n\nExclusion criteria:\n\nNone","ALL","18 Years",{"count":78,"type":79},225,"ESTIMATED","INTERVENTIONAL",[82],"NA","This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.",[85],"Metabolic Dysfunction-associated Steatotic Liver Disease",[87,88,89],"Diabetes","Liver","Obesity","2026-03-30",{"date":92,"type":93},"2026-03-31","ACTUAL",{"date":95,"type":93},"2026-03-16",{"date":97,"type":79},"2030-09",{"name":5,"class":6},1]